ceftibuten (cedax) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ceftibuten is a 3rd generation cephalosporin that is FDA approved for the treatment of acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis. Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis. Common adverse reactions include diarrhea, nausea, vomiting and headache. The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers. Each volunteer was administered one 400-mg ceftibuten capsule. A single dose of liquid antacid did not affect the Cmax or AUC of ceftibuten; however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten Cmax by 23% and ceftibuten AUC by 16%.   NCATS

Chemistry

  • SMILES: NC1=NC(=CS1)C(=C\CC(O)=O)\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O
  • InChIKey: UNJFKXSSGBWRBZ-BJCIPQKHSA-N
  • Mol. Mass: 410.425
  • ALogP: -0.05
  • ChEMBL Molecule:
    ceftibuten  
More Chemistry

Pharmacology

Alternative names

(+)-(6r,7r)-7-((z)-2-(2-amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid | 7-(2-(2-amino-4-thiazolyl)-4-carboxy-2-butenoylamino)-3-cephem-4-carboxylic acid | 7432 s | 7432-s | cedax | cedex | ceftibuten | ceftibuten dihydrate | ceftibutene | ceftibuteno | ceftibutenum | cis-ceftibuten | sch39720 | sch 39720 | sch-39720 | seftem

Organizations (8)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (5)


 

Bronchitis, Chronic (approved 1995)

Otitis Media (approved 1995)

Pharyngitis (approved 1995)

Pyelonephritis

Tonsillitis (approved 1995)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Bacterial Infections (Phase 1)

Healthy Volunteers (Phase 1)

Pharmacokinetics (Phase 1)

Pyelonephritis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue